Dr. Daniel Goldstein discusses the results of a trial of first line pembrolizumab (Keytruda) as first line therapy for patients with metastatic clear cell renal cell carcinoma and the implications for the future role of immunotherapy in RCC. (3:18)
Dr. Daniel Goldstein summarizes the findings of a randomized trial assessing the benefit of adjuvant sunitinib following resection of oligometastatic disease in patients with renal cell carcinoma (RCC). (2:06)
Dr. Daniel Goldstein reviews the key data and limitations from the CARMENA trial that re-evaluated the role of nephrectomy in metastatic renal cell carcinoma (RCC), providing insight into how the data should be applied in clinical practice. (4:37)
Dr. Daniel Goldstein reviews highlights in bladder cancer from ASCO 2018, including the novel agent erdafitinib as a treatment targeting fibroblast growth factor receptor (FGFR) alterations in muscle-invasive, advanced bladder cancer. (2:58)
Dr. Daniel Goldstein reviews provocative and highly promising results with enfortumab, an inhibitor of nectin-4, as a treatment for advanced transitional cell carcinoma of the bladder. (1:57)
Does Nab-Paclitaxel Improve Outcomes Compared to Paclitaxel in Second Line Treatment of Transitional Cell Carcinoma of the Bladder (or other cancers)? Highlights from ASCO 2018 (1:40)
Dr. Daniel Goldstein reviews highlights in bladder cancer from ASCO 2018, including important studies evaluating the efficacy of neoadjuvant immunotherapy instead of chemotherapy for muscle-invasive transitional cell carcinoma of the bladder? (3:34)
Dr. Jack West summarizes findings of a retrospective analysis from Dr. Arbour of MSKCC, evaluating the clinical outcomes of patients with advanced NSCLC on daily steroids while receiving an immune checkpoint inhibitor against PD-1 or PD-L1. (9:06)
Dr. Jack West reviews the remarkable results of the NEJ009 trial that tested the combination of carboplatin/pemetrexed with gefitinib as initial therapy compared to gefitinib followed by chemotherapy in patients with EGFR mutation-positive advanced NSCLC. (12:37)
Dr. Jack West reviews results from ARCHER-1050, a trial of dacomitinib vs. gefitinib, in EGFR mutation-positive NSCLC, asks whether the demonstrated survival benefit is enough to make dacomitinib a player as first line treatment. (7:04)